Figure 5.

Antibody-dependent-cell-mediated cytotoxicity (ADCC) activity of Rituxan^® and _NbRTX^A2G2 with (A) V/V 158 FcγRIIIa (high affinity) and (B) F/F 158 FcγRIIIa (low affinity) variant effector cells (engineered Jurkat cells with FcγRIIIa receptor). All experiments were carried out using human B lymphoma WIL2-S cells and Daudi cells as target cells. The effector cell: target cell ratio was 10:1. Data are expressed as fold of ADCC increase. Values represent mean ± S.D. for triplicate analyses.